GlobeNewswire Inc.··Proqr Therapeutics N.V.ProQR Expands Pipeline With Multiple Clinical Catalysts Lined Up Through 2027
ProQR Therapeutics expands pipeline with lead program AX-0810 targeting H1 2026 data readout in biliary atresia, supported by three additional programs advancing through 2027.
LLYPRQRDNAHurler syndromeclinical pipeline